// Nov 2026
What causes CGT products to receive a CRL during BLA review?
Cell and gene therapy (CGT) products most often receive a complete response letter (CRL) during Biologics License Application (BLA) review because of CMC deficiencies: manufacturing process and materials issues, analytical validation gaps, and unresolved facility inspection findings identified late in the review cycle. FDA requires submission of a BLA and may refuse to file (RTF) an application that does not meet minimum standards, may classify additional submissions during review as major amendments, or issue a CRL citing deficiencies that preclude approval.
Understanding the causes of these regulatory review issues, in particular the reasons cited in CRLs, can inform more effective drug development strategies and strengthen future marketing applications.
Cindy Riggins and I conducted a study and published our finds, 'Understanding FDA's Reasons for Non-Approval: A Systematic Review of Complete Response Letters in Cell and Gene Therapy,' in Cytotherapy.
RTFs were uncommon
Only a few RTFs occurred (3 out of 48 products), which reflected rare but significant deficiencies in initial submissions. The issues were resolved with a delay of 4-6 months.
Major amendments were driven primarily by CMC issues
One-third of the approved products required a major amendment, which extended the review by at least three months. CMC information was the primary driver of major amendments, more so than clinical data. While major amendments extended the review timeline, they typically led to product approval.
CRLs added approximately 23 months to the timeline
Following receipt of a CRL, applicants took a median of approximately 16 months to resubmit their applications. From the initial CRL to final approval, the median delay was roughly 23 months. These findings underscore the considerable impact of CRLs on timelines and stress the importance of proactive strategies to minimize deficiencies to avoid extended review cycles.
CMC deficiencies appeared in every CRL issued. Of the 11 CRLs issued, all of them contained CMC deficiencies, highlighting the complexity of CGT biologics manufacturing. Clinical deficiencies were noted in 36% of letters, and labeling deficiencies in 73%; while CMC issues dominated, other domains also contributed to delays. For CGTs, manufacturing complexity and quality control were the primary regulatory hurdles, unlike traditional drugs where demonstrating efficacy can be the biggest challenge.
Over half of CMC issues were associated with manufacturing processes, process validation, and materials. Analytical procedures, namely inadequate validation, accounted for one-quarter of CMC deficiencies, while product characterization and facility inspection findings contributed to the remaining deficiencies. Deficiencies spanned multiple aspects of manufacturing and quality control, reinforcing the need for comprehensive readiness across all CMC elements.
Nine of 11 CRLs included a deficiency tied to the manufacturing facility inspection
Although negligible association was found between a late pre-license inspection (PLI) and a complete response, products that generally received a complete response had inspections later in their BLA review cycle. In these cases, FDA cited unresolved inspection findings as the basis for the deficiency. Late inspections leave applicants minimal time to address concerns before regulatory action deadlines, whereas earlier inspections provide more opportunity for resolution. Accordingly, applicants should ensure facilities are inspection-ready at the time of BLA submission to facilitate timely inspections and allow time for resolving any inspectional observations.
A 23-month median delay is the price of catching a CMC gap during BLA review instead of during development. Every CRL in this data set cited a CMC deficiency, and manufacturing process and analytical validation issues alone accounted for most of them. The sponsors who avoid that cost catch these gaps in development, not in review. Facility readiness and analytical validation are finished work by the time the BLA goes in, not open items waiting to surface in a deficiency letter.
Read the full study behind this post in Cytotherapy: 'Understanding FDA's Reasons for Non-Approval: A Systematic Review of Complete Response Letters in Cell and Gene Therapy.'
